Clinical Trial Results

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 18

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)

A phase 2 open-label, randomized, multi-center trial to evaluate the efficacy and safety of neoadjuvant trastuzumab, pertuzumab and weekly...

David Page, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Clackamas Clinic
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 and to further evaluate its tolerability and efficacy in expansion...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Clackamas Clinic
  • Providence Cancer Institute Franz Clinic

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (COSMIC-021)

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib...

Matthew Taylor, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD 1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Clackamas Clinic
  • Providence Cancer Institute Franz Clinic

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Patients will receive intratumoral (IT) NKTR-262 in 3-week treatment cycles. During the Phase 1 dose escalation portion of the trial, NKTR-262 will...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

The purpose of this study is to assess the safety and tolerability, characterize the dose-limiting toxicities, and identify the maximum tolerated...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability,...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I Study of GNX102 in patients with Advanced Solid Tumors

GNX-001 is an open-label, phase 1, multicenter, dose-escalation and expansion study of GNX102 infused every 21 days. Approximately 30 patients may...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 18